Takeda Pharmaceutical Company - רווח למניה ב-12 החודשים האחרונים TAK

לוגו של חברה ציבורית Takeda Pharma (TAK)

Analyzing the percentage change in trailing twelve-month EPS dynamics on GURU.Markets, we note that -11.90 serves as the base value for this parameter. Takeda Pharmaceutical (TAK) shares are under pressure due to debt following acquisition deals and generic risks. Price reductions mandated by the Japanese regulator are limiting profit growth. Business stability is maintained by outsourcing early-stage research to external CRO partners.

TAK Takeda Pharmaceutical Company: רווח למניה בשנים עשר החודשים האחרונים בטווח 11.02.2024 - 17.11.2026

פילוחי מדדים פיננסיים ומדדי שוק עבור Takeda Pharmaceutical Company Limited (TAK)

- שער מניה ותחזית מחירי מומחים:
הערכת שווי פונדמנטלית של החברה:TAK - Takeda Pharmaceutical Company
מוצר ממותג של Takeda Pharmaceutical Company

The EPS TTM YoY dynamics mathematically reflect the efficiency of converting operating revenue into net income per share over a rolling year. This indicator measures the actual speed of profitability recovery while excluding one-off distortions. For Takeda Pharmaceutical (TAK), this calculation is critical due to pricing pressure from Japanese regulators and patent expirations. By analyzing the current EPS TTM YoY growth rate, investors assess the ecosystem's ability to offset losses from legacy blockbusters with new drugs.